Tailoring of hormonal therapy in prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 3, Issue 1, 2000, Pages 21-27

  Newling, D W W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hormonal therapy; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; BROMOCRIPTINE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; NILUTAMIDE; STEROID;

ALGORITHM; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CASTRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT PLANNING;

EID: 0033866220     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500400     Document Type: Review

References (34)

1. Assessment of hormone refractory prostate cancer
2. Clinical trials in relapsed prostate cancer: Defining the target
3. Reasons for delay of endocrine treatment in cancer of the prostate (until symptomatic metastases occur)
4. Immediate vs deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial
5. Early orchectomy for patients with stage D1 prostatic carcinoma
6. Prostate cancer outcomes study: A population based study of the treatment of prostate cancer
7. The final analysis of the EORTC phase Ill clinical trial (30805) comparing orchiectomy, orchiectomy plus cyproterone acetate and low dose stilbestrol in the management of metastatic carcinoma of the prostate
8. Osteoporosis after ochiectomy for prostate cancer
9. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate cancer
10. Autocrine stimulation by GnRH like factors in hormone responsive prostate cancer cells in culture
11. Responses to the antagonist analogue of LHRH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
12. A randomised comparison of Casodex (bicalutamide 150mg monotherapy vs castration in the treatment of metastatic and locally advanced prostate cancer
13. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
14. Monotherapy with nilutamide, a pure non-steroidal anti-androgen, in untreated patients with metastatic carcinoma of the prostate
15. Casodex 10-200 mgm daily used as monotherapy for the treatment of patients with advanced prostate cancer
16. Cyproterone acetate as monotherapy in prospective randomized trials
17. Early orchidectomy for patients with stage D1 prostatic cardnoma
18. Antiandrogene in der Therapie des fortgeschritten Prostatakarzinoms
19. The VACURG studies of cancer of the prostate
20. Long-term results of the Danish Prostate Group trial 86
21. A phase II trial of oral DES as a second line hormonal age in advanced prostate cancer
22. Present procedures in the treatment of prostate cancer
23. The final analysis of the EORTC phase III clinical trial (30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilbestrol in the management of metastatic carcinoma of the prostate
24. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
25. A controlled trial of leuprolide with and without flutamide in prostate cancer
26. Orchidectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
27. Maximal androgen blockade: Final analysis of EORTC phase Ill trial 30853
28. A randomised comparison of Casodex (bicalutamide) 150mg monotherapy vs castration in the treatment of metastatic and locally advanced prostate cancer
29. Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side-effects
30. Reasons against total androgen suppression
31. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: Results of NCI intergroup study 0105 (SWOG and ECOG)
32. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
33. Prospective determinations of the hormonal response after cessation of LHRH-agonist treatment in patients with prostatic cancer